Synaptic degeneration in Alzheimer disease

M Tzioras, RI McGeachan, CS Durrant… - Nature Reviews …, 2023 - nature.com
Alzheimer disease (AD) is characterized by progressive cognitive decline in older
individuals accompanied by the presence of two pathological protein aggregates—amyloid …

The amyloid-β pathway in Alzheimer's disease

H Hampel, J Hardy, K Blennow, C Chen, G Perry… - Molecular …, 2021 - nature.com
Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

[HTML][HTML] Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: A systematic review

D Jeremic, L Jiménez-Díaz, JD Navarro-López - Ageing research reviews, 2021 - Elsevier
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …

If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?

C Haass, D Selkoe - PLoS biology, 2022 - journals.plos.org
Strong genetic evidence supports an imbalance between production and clearance of
amyloid β-protein (Aβ) in people with Alzheimer disease (AD). Microglia that are potentially …

Phosphorylated tau in Alzheimer's disease and other tauopathies

P Rawat, U Sehar, J Bisht, A Selman… - International Journal of …, 2022 - mdpi.com
Alzheimer's disease (AD) is the leading cause of dementia in elderly people. Amyloid beta
(Aβ) deposits and neurofibrillary tangles are the major pathological features in an …

[HTML][HTML] Anti-amyloid immunotherapies for Alzheimer's disease: a 2023 clinical update

G Yadollahikhales, JC Rojas - Neurotherapeutics, 2023 - Elsevier
The amyloid cascade hypothesis is a useful framework for therapeutic development in
Alzheimer's disease (AD). Amyloid b 1-42 (Aβ) has been the main target of experimental …

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease

NR Barthélemy, Y Li, N Joseph-Mathurin, BA Gordon… - Nature medicine, 2020 - nature.com
Abstract Development of tau-based therapies for Alzheimer's disease requires an
understanding of the timing of disease-related changes in tau. We quantified the …

[HTML][HTML] Interaction between Aβ and tau in the pathogenesis of Alzheimer's disease

H Zhang, W Wei, M Zhao, L Ma, X Jiang… - … journal of biological …, 2021 - ncbi.nlm.nih.gov
Extracellular neuritic plaques composed of amyloid‑β (Aβ) protein and intracellular
neurofibrillary tangles containing phosphorylated tau protein are the two hallmark proteins of …

Stress granules and neurodegeneration

B Wolozin, P Ivanov - Nature Reviews Neuroscience, 2019 - nature.com
Recent advances suggest that the response of RNA metabolism to stress has an important
role in the pathophysiology of neurodegenerative diseases, particularly amyotrophic lateral …

[HTML][HTML] Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy

T Wu, B Dejanovic, VD Gandham, A Gogineni… - Cell reports, 2019 - cell.com
Complement pathway overactivation can lead to neuronal damage in various neurological
diseases. Although Alzheimer's disease (AD) is characterized by β-amyloid plaques and tau …